With significant advances in systemic therapy, particularly the extensive use of PD-1/PD-L1 inhibitors in HCC, the continued evaluation of FOLFOX-HAIC along with lenvatinib and durvalumab for the treatment of unresectable ICC is warranted. This evidence concerns the gene CD274 and intrahepatic cholangiocarcinoma.